Orchestra BioMed (OBIO) insider sale under 10b5-1 plan on August 3, 2026

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. executive Darren Sherman reported selling 15,000 shares of common stock on August 3, 2026 at a weighted average price of $4.09 per share, in trades ranging from $3.94 to $4.15, under a Rule 10b5-1 trading plan adopted on December 18, 2025. Following the sale, he directly held 1,154,327 shares.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 1 txn

Insider Sherman Darren

Role See Remarks

Sold 15,000 shs ($61K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share F1, F2	15,000	$4.09	$61K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 1,154,327 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.
2. F2. The price reported is a weighted average price. These shares were disposed in multiple transactions at prices ranging from $3.94 to $4.15. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares disposed at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 15,000 shares Weighted average sale price: $4.09 per share Sale price range: $3.94–$4.15 per share +2 more

5 metrics

Shares sold 15,000 shares Non-derivative common stock sale on August 3, 2026 by Darren Sherman

Weighted average sale price $4.09 per share Average price for 15,000 shares sold on August 3, 2026

Sale price range $3.94–$4.15 per share Multiple transactions within this range for the reported sale

Shares held after transaction 1,154,327 shares Direct common stock ownership by Darren Sherman following the sale

Rule 10b5-1 plan adoption date December 18, 2025 Trading plan under which the August 3, 2026 sale was executed

Key Terms

Rule 10b5-1 trading plan, weighted average price, Common Stock, par value $0.0001 per share

3 terms

Rule 10b5-1 trading plan financial

"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were disposed"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock, par value $0.0001 per share financial

"security_title: Common Stock, par value $0.0001 per share"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:50 PM Accepted by SEC EDGAR 08/04/2026 - 04:49 PM Learn about SEC filing dates

FAQ

What insider transaction did Darren Sherman report for Orchestra BioMed (OBIO)?

Darren Sherman reported a sale of 15,000 shares of Orchestra BioMed common stock on August 3, 2026. The transaction involved non-derivative common shares and was executed as a planned sale under a Rule 10b5-1 trading plan adopted earlier.

At what prices were the OBIO shares sold in Darren Sherman’s Form 4?

The 15,000 OBIO shares were sold at a weighted average price of $4.09 per share. According to the disclosure, individual trades occurred in multiple transactions at prices ranging from $3.94 to $4.15 per share on August 3, 2026.

How many Orchestra BioMed (OBIO) shares does Darren Sherman hold after this sale?

After the reported sale, Darren Sherman directly held 1,154,327 shares of Orchestra BioMed common stock. This figure represents his direct ownership position immediately following the August 3, 2026 transaction disclosed in the insider trading report.

Was Darren Sherman’s OBIO share sale made under a Rule 10b5-1 plan?

Yes. The sales were effected under a Rule 10b5-1 trading plan adopted by Darren Sherman on December 18, 2025. Such plans allow pre-arranged trading instructions, meaning the timing of the August 3, 2026 sale followed that preset arrangement.

What is Darren Sherman’s role at Orchestra BioMed (OBIO) related to this insider filing?

Darren Sherman is identified as the company’s President and Chief Operating Officer, and also a director. His senior executive position makes his equity transactions reportable, leading to this Form 4 detailing the August 3, 2026 sale of common stock.

What type of security did Darren Sherman sell in his OBIO Form 4 filing?

The transaction involved Common Stock, par value $0.0001 per share of Orchestra BioMed Holdings, Inc. The filing describes this as a non-derivative security, indicating it was direct common equity rather than options, warrants, or other derivative instruments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sherman Darren

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PENNSYLVANIA 18938

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/03/2026		S(1)		15,000	D	$4.09(2)	1,154,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.

2. The price reported is a weighted average price. These shares were disposed in multiple transactions at prices ranging from $3.94 to $4.15. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares disposed at each separate price within the range set forth in this footnote.

Remarks:

President and Chief Operating Officer

	/s/ Andrew Taylor, Attorney-in-Fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)